Merus

What Merus does

Merus N.V. was a Dutch clinical-stage immuno-oncology company founded in 2003 and headquartered in Utrecht, the Netherlands, with a U.S. subsidiary in Cambridge, Massachusetts. The company developed multispecific antibody therapeutics for cancer using its proprietary Multiclonics® platform, which comprises three modular formats — Biclonics® for bispecific antibodies, Triclonics® for trispecific antibodies, and ADClonics® for bispecific antibody-drug conjugates. These formats enable high-yield manufacturing in a standard IgG architecture without linkers or fusion proteins, with candidate identification driven by high-throughput functional screening.

The company's pipeline included the FDA-approved BIZENGRI® (zenocutuzumab-zbco), a HER2×HER3 bispecific approved in December 2024 under accelerated approval for NRG1 fusion-positive NSCLC and pancreatic adenocarcinoma; the lead clinical asset petosemtamab (MCLA-158), an EGFR×LGR5 bispecific in Phase 3 trials for head and neck squamous cell carcinoma and being evaluated in metastatic colorectal cancer; and earlier-stage candidates MCLA-129 (EGFR×c-MET), MCLA-145 (CD137×PD-L1), and MCLA-117 (CLEC12A×CD3 T-cell engager).

Merus operated a partnership-driven business model, generating revenue from upfront payments, development and commercial milestones, and royalties from collaborators including Incyte (up to 11 programs), Eli Lilly (CD3 bispecifics), Gilead (Triclonics®, up to $1.5 billion potential), Biohaven (ADCs), Betta Pharmaceuticals (China), and Ono Pharmaceutical (Japan). U.S. commercialization of BIZENGRI was licensed exclusively to Partner Therapeutics. The company was acquired by Genmab A/S for approximately $8 billion in an all-cash transaction completed on December 30, 2025, after which Merus delisted from Nasdaq and became a wholly-owned subsidiary with Genmab executives assuming its leadership.

Name

Merus

Legal name

Merus N.V.

Website

https://merus.nl

Company type

Private

Founded year

2003

Operating status

Acquired

Headcount range

251–500 employees

Short description

Merus N.V. is a Dutch clinical-stage immuno-oncology company developing bispecific and trispecific antibody therapeutics through its proprietary Multiclonics® platform, serving cancer patients with lead assets including the FDA-approved BIZENGRI® and Phase 3 candidate petosemtamab. Acquired by Genmab for ~$8 billion in December 2025.

Ownership category

akta.pro rank

Product category

Bispecific Antibody Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Bispecific & Multispecific Antibodies (HLAAAAAF)

Keywords

• Bispecific antibody therapeutics
• Immuno-oncology drugs
• Trispecific antibody development
• Antibody-drug conjugates
• Cancer treatment pipeline

Headquarters

HQ city

Utrecht

HQ country

Netherlands

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Collaboration and Licensing Revenue: Merus generates revenue through strategic collaborations with pharmaceutical companies including upfront payments, milestone payments (development and commercialization), and tiered royalty payments on product sales. Key partners include Incyte (up to 11 programs), Eli Lilly (CD3 bispecifics), Gilead (Triclonics®, up to $1.5B potential), Biohaven (ADCs), and regional partners Betta Pharmaceuticals and Ono Pharmaceutical.
2. Product Sales (BIZENGRI): Following FDA accelerated approval of BIZENGRI (zenocutuzumab-zbco) in December 2024 for NRG1 fusion-positive NSCLC and pancreatic adenocarcinoma, Merus receives product revenue through its licensing agreement with Partner Therapeutics for U.S. commercialization.
3. Public Equity Offerings: The company has historically raised capital through public offerings of common shares. Prior to acquisition by Genmab, Merus conducted multiple offerings: $400.2M (May 2024), $150M (August 2023), $300M (June 2025), and $110M (November 2021).

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Merus discovers and develops multispecific antibody therapeutics (bispecific and trispecific) for cancer treatment using its proprietary Multiclonics platform (Biclonics, Triclonics, ADClonics). The company has one FDA-approved product, BIZENGRI (zenocutuzumab-zbco), for NRG1 fusion-positive cancers, and a pipeline of clinical-stage candidates led by petosemtamab for head and neck cancer.

Product overview

Merus is a clinical-stage immuno-oncology company developing multispecific antibody therapeutics. The company operates two proprietary technology platforms (Biclonics® for bispecific and Triclonics® for trispecific antibodies) and a related ADClonics® antibody-drug conjugate platform. The marketed product BIZENGRI® (zenocutuzumab-zbco) received FDA accelerated approval in December 2024 for NRG1 fusion-positive cancers. The lead clinical candidate is petosemtamab (MCLA-158), an EGFR×LGR5 bispecific antibody in Phase III trials for head and neck cancer. Additional pipeline candidates include MCLA-129 (EGFR×c-MET), MCLA-145 (CD137×PD-L1), and MCLA-117 (CLEC12A×CD3 T-cell engager). Merus was acquired by Genmab in December 2025 for approximately $8 billion.

Differentiator

Problem solved

Functional benefit

Products and services

• BIZENGRI (zenocutuzumab-zbco) FDA-approved bispecific antibody targeting HER2 and HER3 for treatment of adults with advanced unresectable or metastatic NRG1 fusion-positive pancreatic adenocarcinoma or non-small cell lung cancer. Approved under accelerated approval based on response rate and duration of response.
• Petosemtamab (MCLA-158) Lead bispecific antibody therapeutic candidate targeting EGFR and LGR5 in Phase 3 registrational trials for head and neck squamous cell carcinoma (HNSCC) and being evaluated in metastatic colorectal cancer. Showing single agent clinical activity in previously treated recurrent/metastatic head and neck cancer and in combination with pembrolizumab in first-line PD-L1+ head and neck cancer. Received FDA Breakthrough Therapy Designation.
• MCLA-129 Bispecific antibody targeting EGFR and c-MET in clinical development for non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations and head and neck squamous cell carcinoma. Also being evaluated in combination with osimertinib.
• MCLA-145 Bispecific antibody targeting CD137 and PD-L1 in Phase 1 clinical study for solid tumors, as monotherapy or in combination with pembrolizumab.
• MCLA-117 Bispecific T-cell engager targeting CLEC12A and CD3 in clinical development for acute myelogenous leukemia (AML).
• Biclonics Platform Proprietary bispecific antibody technology platform that generates diverse panels of antibodies and enables functional screening at high throughput to discover therapeutic candidates with unique properties. Does not require linkers or modifications to force correct pairing of heavy and light chains. Licensed to pharmaceutical partners for collaborative drug discovery and development.
• Triclonics Platform Proprietary trispecific antibody technology platform capable of simultaneously binding three targets. Has potential to enable tumor cell-killing activity and/or modulate the immune system for more robust anti-tumor immune responses. Licensed to Gilead Sciences for T-cell engaging multi-specific antibody products.
• ADClonics Platform Antibody-drug conjugate platform utilizing the Biclonics format with a range of linkers and payloads to generate ADCs capable of binding two different targets for improved binding selectivity, internalization, and cancer cell killing activity. Co-developed with Biohaven Pharmaceutical for three novel bispecific ADCs.

Quantifiable outcome

• 100% response rate in first-line left-sided metastatic colorectal cancer patients in Phase 2 trial of petosemtamab monotherapy
• +2 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core, flagship and regional.

• Halozyme TherapeuticscoreTechnology or Integration · 17 November 2025Global non-exclusive collaboration and license agreement to develop a subcutaneous formulation of petosemtamab using Halozyme's ENHANZE drug delivery technology. Merus makes upfront payment plus potential milestone payments tied to commercial and sales attainment. Halozyme receives low-mid single digit royalties on net sales.
• Biohaven PharmaceuticalcoreStrategic or Co-development Partner · 1 January 2025Collaboration and license agreement to co-develop three novel bispecific antibody drug conjugates (ADCs), leveraging Merus' Biclonics technology platform and Biohaven's next-generation ADC conjugation and payload platform technologies.
• Gilead SciencesflagshipStrategic or Co-development Partner · 1 March 2024Collaboration, option and license agreement to use Merus' Triclonics platform to develop T-cell engaging multi-specific antibody products in oncology. Gilead paid $56 million upfront and $25 million equity investment. Potential up to $1.5 billion across three programs plus royalties. Merus can opt for 50/50 profit/loss split on third program.
• Eli Lilly and CompanycoreStrategic or Co-development Partner · 1 January 2021Research collaboration and exclusive license agreement leveraging Merus' Biclonics platform to research and develop up to three CD3-engaging T-cell redirecting bispecific antibody therapies. Merus leads discovery and early-stage research funded by Lilly, which is responsible for further development and commercialization.
• Betta PharmaceuticalsregionalStrategic or Co-development Partner · 1 January 2019Strategic collaboration to develop and commercialize Merus' Biclonics MCLA-129 in China. Betta Pharmaceuticals is responsible for clinical development and potential commercialization in China, while Merus retains full ex-China rights.
• Incyte CorporationcoreStrategic or Co-development Partner · 1 December 2016Global strategic collaboration focused on research, discovery and development of bispecific antibodies utilizing Merus' proprietary Biclonics technology platform. Incyte received exclusive rights for up to eleven bispecific or monospecific antibody research programs.
• Ono PharmaceuticalregionalStrategic or Co-development Partner · 1 April 2014Research and license agreement to jointly develop bispecific antibody therapies for undisclosed targets. Ono received worldwide exclusive rights to develop, manufacture, and commercialize resulting products. Merus received upfront payment and is eligible for milestones and sales royalties. Extended in March 2018 for additional bispecific antibody.
• Partner TherapeuticsflagshipChannel Partner/ Reseller/ DistributorPartner Therapeutics has exclusive license for commercialization of BIZENGRI (zenocutuzumab-zbco) in the U.S. market. PTx Assist program provides patient access and insurance support at 1-877-353-8546.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Genmab: Genmab A/S is a Danish antibody therapeutics company that acquired Merus in December 2025; it developed and commercializes epcoritamab (Epkinly) with AbbVie and Darzalex with Janssen, making it both the parent company and the most directly comparable antibody-engineering platform company to Merus.
• Roche: Roche has commercialized multiple bispecific antibodies including mosunetuzumab (Lunsumio) and glofitamab (Columvi) in B-cell lymphomas, positioning it as a broad incumbent with overlapping bispecific antibody franchise capabilities to Merus.
• AbbVie: AbbVie co-develops and commercializes epcoritamab (Epkinly) with Genmab in hematologic malignancies, representing a broad incumbent peer with significant bispecific antibody commercial presence overlapping Merus' oncology pipeline.
• Regeneron: Regeneron has developed bispecific antibodies including linvoseltamab (BCMAxCD3) and odronextamab (CD20xCD3), and through Regeneron Bioventures invested in bispecific antibody discovery — overlapping oncology focus with Merus' lead clinical assets.
• AstraZeneca: AstraZeneca has multiple bispecific antibody programs in oncology, including those developed through its Alexion and AstraZeneca oncology franchises, and is a significant antibody therapeutics player whose pipeline overlaps with Merus' oncology focus.

Direct peers

• MacroGenics: MacroGenics develops bispecific antibodies using its proprietary DART and TRIDENT platforms for cancer immunotherapy, with clinical assets targeting HER2, PD-1, and immune checkpoints — directly comparable to Merus' Biclonics bispecific pipeline.
• Zymeworks: Zymeworks develops multispecific antibody therapeutics using its Azymetric and EFECT platforms, including bispecific antibodies in oncology indications — overlapping technology approach and therapeutic focus with Merus' Multiclonics platform.
• Xencor: Xencor engineers bispecific and multispecific antibodies using its XmAb platform, with clinical assets in oncology and autoimmune disease — a direct technology and therapeutic area peer to Merus' bispecific antibody discovery capabilities.
• Akeso: Akeso is a Chinese biotech that has emerged as a leader in bispecific antibodies, most notably with ivonescimab (PD-1xVEGF) for NSCLC — a direct therapeutic and modality competitor to Merus' EGFRxLGR5 and other bispecific oncology assets.

Others

• Eli Lilly: Eli Lilly is both a Merus collaboration partner (CD3 bispecific T-cell engagers using Biclonics platform) and a broader biopharma peer; it advances its own bispecific antibody portfolio (including through Loxo@Lilly) and provides a relevant comparator for licensing economics and large-pharma platform partnerships.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/MerusNV
• LinkedInlinkedin.com/company/merus

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds12 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Merus